: Monday, April 19, 2021, 3:49 PM IST
Markets crash by over 1,200 points today: Jubilant Pharmova, Thyrocare, Dr Reddy, Pfizer, Dr Lal PathLabs among other healthcare stocks trade in green
Market crash by over 1,200 points today: Jubilant Pharmova, Thyrocare, Dr Reddy, Pfizer, Lal PathLabs among other healthcare stocks perform
After a decline of 1,257.56 points in the opening session, Sensex continued to be volatile. At 3 pm, it was down by 800 points, since the morning crash it has recovered by over 400 points. Meanwhile, Nifty in early trade was down by 379.10 points to 14,238.75.
While the whole market is struggling due to this bear run, there are some indices that are able to hold on. Healthcare and information technology stocks did trade in green despite the slump in market. Some healthcare stocks did well due to the rise in cases of COVID-19 and its direct impact on their business.
Dr A Velumani, managing director of
Thyrocare Technologies talks of the hold up in testing and why the problem is universal.
What is happening with the availability of testing kits? Reports suggest there is a huge shortage of RT-PCR kits, is that true? Is there enough capacity right now to fulfil the obligation of having 70% of all tests be RT-PCR in the state?
There is no shortage of reagents, what is probably happening is that there is no more capacity. What that means is that laboratories are at their total capacity. If a city like Mumbai has the capacity to do 50,000 tests a day and demand rises to 2,00,000, there s no way the city can do it. All these premises have limitation, you can t just start a new one.
COVID-19 test labs across the country are at their limits, says Thyrocare Tech MD, Dr Velumani
SECTIONS
Last Updated: Apr 14, 2021, 12:56 PM IST
Share
Synopsis
We came down to as little as 20% capacity in January, but, in these last eight weeks there has been 100% growth, every week. Amidst these rising loads, we cannot do more, without more people, says Dr Velumani.
Agencies Dr A Velumani, managing director of
Thyrocare Technologies talks of the hold up in testing and why the problem is universal.
What is happening with the availability of testing kits? Reports suggest there is a huge shortage of RT-PCR kits, is that true? Is there enough capacity right now to fulfil the obligation of having 70% of all tests be RT-PCR in the state?
Read more about Anupam Rasayan IPO subscribed 1.29 times on Business Standard. The issue received bids for 1.25 crore shares as against 97.01 lakh shares on offer
The issue received bids for 240.27 crore shares as against 1.50 crore shares on offer.The initial public offer (IPO) of Easy Trip Planners received bids for 240.27 crore shares as against 1.50 crore shares on offer, according to the stock exchange data. The issue was subscribed 159.33 times.
The non-institutional investors category was subscribed 382.21 times. The qualified institutional buyers (QIBs) category was subscribed 77.53 times. The retail individual investors category was subscribed 70.40 times.
The issue opened for bidding on Monday, 8 March 2021, and closed on Wednesday, 10 March 2021. The price band for the IPO was set at Rs 186-187 per share.
The IPO comprised an offer for sale (OFS) of equity shares aggregating up to Rs 510 crore (including anchor portion of 1,22,72,727 equity shares). The post-issue promoter s shareholding in the company will decline to 74.9% from 100%.